Back to top
Redhill Biopharma (RDHL)
(Real Time Quote from BATS)
$0.40 USD
0.40
473,694
+0.01 (3.76%)
Updated Apr 18, 2024 01:42 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Income Statements
Fiscal Year end for Redhill Biopharma Ltd falls in the month of December .
All items in Millions except EPS data.
| 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
|---|---|---|---|---|---|
| Sales | 7 | 62 | 86 | 64 | 6 |
| Cost Of Goods | 3 | 33 | 49 | 37 | 2 |
| Gross Profit | 3 | 28 | 36 | 27 | 4 |
| Selling & Adminstrative & Depr. & Amort Expenses | -10 | 71 | 117 | 91 | 47 |
| Income After Depreciation & Amortization | 13 | -43 | -81 | -64 | -43 |
| Non-Operating Income | 21 | 14 | 0 | 0 | 1 |
| Interest Expense | 10 | 42 | 17 | 13 | 0 |
| Pretax Income | 24 | -72 | -98 | -76 | -42 |
| Income Taxes | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
| Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
| Income From Cont. Operations | 24 | -72 | -98 | -76 | -42 |
| Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Net Income (GAAP) | 24 | -72 | -98 | -76 | -42 |
| Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
|---|---|---|---|---|---|
| Income Before Depreciation & Amortization | 15 | -35 | -79 | -62 | -42 |
| Depreciation & Amortization (Cash Flow) | 2 | 8 | 2 | 2 | 1 |
| Income After Depreciation & Amortization | 13 | -43 | -81 | -64 | -43 |
| Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
|---|---|---|---|---|---|
| Average Shares | 6.48 | 1.55 | 1.16 | 0.91 | 0.74 |
| Diluted EPS Before Non-Recurring Items | 3.69 | -46.30 | -84.00 | -84.00 | -56.00 |
| Diluted Net EPS (GAAP) | 4.00 | -48.00 | -84.00 | -84.00 | -56.00 |
Fiscal Year end for Redhill Biopharma Ltd falls in the month of December .
All items in Millions except EPS data.
| 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
|---|---|---|---|---|---|
| Sales | NA | NA | NA | 1.80 | 3.60 |
| Cost Of Goods | NA | NA | NA | NA | 1.61 |
| Gross Profit | NA | NA | NA | NA | 1.99 |
| SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -27.10 |
| Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 29.09 |
| Non-Operating Income | NA | NA | NA | NA | 21.58 |
| Interest Expense | NA | NA | NA | NA | 0.42 |
| Pretax Income | NA | NA | NA | NA | 50.24 |
| Income Taxes | NA | NA | NA | NA | NA |
| Minority Interest | NA | NA | NA | NA | NA |
| Investment Gains/Losses | NA | NA | NA | NA | NA |
| Other Income/Charges | NA | NA | NA | NA | NA |
| Income From Cont. Operations | NA | NA | NA | 101.24 | 50.24 |
| Extras & Discontinued Operations | NA | NA | NA | 0.00 | 0.00 |
| Net Income (GAAP) | NA | NA | NA | 101.24 | 50.24 |
| Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
|---|---|---|---|---|---|
| Average Shares | NA | NA | NA | 2.81 | 2.51 |
| Diluted EPS Before Non-Recurring Items | NA | NA | NA | 36.00 | 5.87 |
| Diluted Net EPS (GAAP) | NA | NA | NA | 36.00 | 20.00 |